In type 2 diabetes, counterregulatory responses have both been reported to be unaffected [16–18] or reduced [6], with counterregulatory failure being described in those with reduced beta-cell function in longstanding disease [6] and the prevalence of IAH averaging 10% in those using insulin [19]. This evidence concerns the gene INS and type 2 diabetes mellitus.